Medium-term and peri-lockdown course of psychosocial burden during the ongoing COVID-19 pandemic: a longitudinal study on patients with pre-existing mental disorders
- PMID: 34825249
- PMCID: PMC8614217
- DOI: 10.1007/s00406-021-01351-y
Medium-term and peri-lockdown course of psychosocial burden during the ongoing COVID-19 pandemic: a longitudinal study on patients with pre-existing mental disorders
Abstract
While the COVID-19 pandemic continues, patients with pre-existing mental disorders are increasingly recognized as a risk group for adverse outcomes. However, data are conflicting and cover only short time spans so far. Here, we investigate the medium-term and peri-lockdown-related changes of mental health outcomes in such patients in a longitudinal study. A cohort of 159 patients comprising all major mental disorders (ICD-10 F0-F9) were interviewed twice with the Goettingen psychosocial Burden and Symptom Inventory (Goe-BSI) to evaluate psychosocial burden, psychiatric symptoms and resilience at the end of the first (April/May 2020) and the second lockdown in Germany (November/December 2020). For the primary outcome "psychosocial burden" ratings also comprised retrospective pre-pandemic (early 2020) and very early states during the pandemic (March 2020). For all diagnostic groups, psychosocial burden varied significantly over time (p < 0.001) with an increase from the pre-pandemic to the initial phase (p < 0.001), followed by a steady decrease across both lockdowns, normalizing in November/December 2020. Female gender, high adjustment disorder symptom load at baseline and psychiatric comorbidities were risk factors for higher levels and an unfavorable course of psychosocial burden. Most psychiatric symptoms changed minimally, while resilience decreased over time (p = 0.044 and p = 0.037). The longitudinal course of psychosocial burden indicates an initial stress response, followed by a return to pre-pandemic levels even under recurrent lockdown conditions, mimicking symptoms of an adjustment disorder. Strategies for proactive, specific and continuous treatment have to address resilience capacities before their depletion in the pandemic aftermath, especially for patients with additional risk factors.
Keywords: Adjustment disorder; Coronavirus; Mental health; Psychosocial stress; SARS-CoV-2.
© 2021. The Author(s).
Conflict of interest statement
All authors report no financial relationships with commercial interests related to this article. Beyond that, CB receives honoraria as a diagnostic consultant for Boehringer Ingelheim and received honoria for lectures from Roche. CB, PH, MAH, KR, and MB receive funding from the German Alzheimer Association. US is consultant for Boehringer Ingelheim, Germany. BHS holds grants from the German Research Foundation (DFG), as well as the European Union and the State of Saxony-Anhalt (Research Alliance “Autonomy in Old Age”). JW is supported by an Ilídio Pinho professorship, iBiMED (UIDB/04501/2020) at the University of Aveiro, Portugal. JW is an advisory board member of Abbott, Biogen, Boehringer Ingelheim, Immunogenetics, Lilly, MSD Sharp & Dohme, and Roche Pharma. JW received honoraria for lectures from the AGNP, Actelion, Amgen, Beeijing Yibai Science and Technology Ltd., CSF-Society, Helios Klinikum Wuppertal, Janssen Cilag, Med Update GmbH, Pfizer, Roche Pharma, Vitos Kurhessen-Bad Emstal, as well as funding from the German Federal Ministry for Education and Research (BMBF), the European Union (EU), and the German Research Foundation (DFG). JW holds the following patents: PCT/EP 2011 001724 and PCT/EP 2015 052945. CWM advises Janssen Cilag and LivaNova on an honorary basis. He advises the following hospitals and the hospital company: Amelung Klinik, hospital company: Mecklenburg-Vorpommern, Berlin-Brandenburg, Niedersachsen. CWM completes seminars for: mibeg institutes, PKM.
Figures


Comment in
-
Mental health during the COVID-19 pandemic, impact of childhood trauma in psychiatric disorders, and predictable biomarkers for bipolar disorder.Eur Arch Psychiatry Clin Neurosci. 2022 Aug;272(5):753-755. doi: 10.1007/s00406-022-01445-1. Eur Arch Psychiatry Clin Neurosci. 2022. PMID: 35751656 Free PMC article. No abstract available.
References
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous